-
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies,
such as gemtuzumab, can block cancer growth in different ways. Some find cancer cells and
help kill them or carry cancer-killing substances to them. Others interfere with the ability
of cancer cells to grow and spread. Gemtuzumab may also stop the growth of promyelocytic
leukemia by blocking blood flow to the cancer. Giving gemtuzumab together with combination
chemotherapy may be more effective in treating promyelocytic leukemia.
PURPOSE: This phase II trial is studying how well giving gemtuzumab together with combination
chemotherapy works in treating patients with previously untreated promyelocytic leukemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nini Estevez, 6507254041.
Stanford Investigators
View full details
-
A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Not Recruiting
More
This Phase 3, randomized, double-blind, placebo-controlled study is to evaluate the effect of
idelalisib in combination with rituximab on the onset, magnitude, and duration of tumor
control in participants previously treated for chronic lymphocytic leukemia (CLL). Eligible
patients will be randomized with a 1:1 ratio into 1 of the 2 treatment arms to receive either
idelalisib plus rituximab or placebo plus rituximab. Participants who are tolerating primary
study therapy but experience definitive CLL progression are eligible to receive active
idelalisib therapy in the extension study, GS-US-312-0117.
Stanford is currently not accepting patients for this trial.
For more information, please contact Tessa Hunter, 6507364032.
Stanford Investigators
View full details
-
Integrated Whole-Genome Analysis of Hematologic Disorders
Not Recruiting
More
We will use new technologies to look at the DNA, RNA, proteins, and metabolites in the
disease-containing blood, bone marrow, or tissue and normal cells from the skin. Our goal is
to analyze all of the genes in the diseased and normal skin sample. By comparing the results
of the diseased sample and normal skin cells and the results of the two types of genetic
information (DNA and RNA), we should be able to identify genetic changes that are important
for the initiation, progression, or treatment response of that particular disorder.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jason D Merker, 650-922-1885.
Lead Sponsor
Stanford Investigators
View full details
-
Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
Not Recruiting
More
The safety and efficacy of midostaurin (PKC412), a novel investigational drug, will be
evaluated on the basis of response rate, when administered to patients with aggressive
systemic mastocytosis (ASM) or mast cell leukemia (MCL)
Stanford is currently not accepting patients for this trial.
For more information, please contact Andrea Linder, 6507254047.
Stanford Investigators
View full details
-
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Not Recruiting
More
This randomized phase III trial studies lenalidomide to see how well it works with or without
epoetin alfa in treating patients with myelodysplastic syndrome and anemia. Lenalidomide may
stop the growth of myelodysplastic syndrome by blocking blood flow to the cells. Colony
stimulating factors, such as epoetin alfa, may increase the number of immune cells found in
bone marrow or peripheral blood. It is not yet known whether lenalidomide is more effective
with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Mai Tran, 6507238594.
Stanford Investigators
View full details
-
To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.
Not Recruiting
More
The purpose of this study is to compare the response of patients with Intermediate or High
Risk myelodysplastic syndromes (MDS) following treatment with decitabine or azacitidine.
Stanford is currently not accepting patients for this trial.
For more information, please contact Mai Tran, 6507238594.
Stanford Investigators
View full details
-
Biomarker To Evaluate Protein Profiles of Neutropenic Fever/Infection With Acute or Chronic Leukemias
Not Recruiting
More
The purpose of this study is to measure, in pilot/observational study, panels of circulating
proteins in real time at the onset of neutropenic fever/infection in patients with acute or
chronic leukemias undergoing chemotherapy or other biologic treatment. And to generate
preliminary trend results in panels of circulating proteins longitudinally during the period
of neutropenia and to correlate those values to clinical/laboratory data and patient
outcomes.
Stanford is currently not accepting patients for this trial.
For more information, please contact Andrea Linder, 6507254047.
Lead Sponsor
Stanford Investigators
View full details
-
A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)
Not Recruiting
More
The primary objectives of the trial are to assess erythroid response to darbepoetin alfa, as
determined by changes in hemoglobin and/or red blood cell (RBC) transfusion-dependence and to
describe the safety profile of darbepoetin alfa in patients with MDS. The secondary objective
is to assess bone marrow progenitor BFU-E growth before and after treatment with darbepoetin
alfa.
Stanford is currently not accepting patients for this trial.
For more information, please contact Mai Tran, 6507238594.
Stanford Investigators
View full details
-
A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL
Not Recruiting
More
This study is to evaluate the safety and clinical activity of idelalisib alone and in
combination with rituximab in patients with CLL or SLL.
This Phase 2 study will be the first time that idelalisib is administered to previously
untreated patients with hematologic malignancies. Idelalisib has demonstrated clinical
activity as a single agent in relapsed or refractory CLL and SLL with acceptable toxicity,
which supports its evaluation in previously untreated patients. The study population is
limited to patients over 65 years of age because younger patients are generally appropriate
for standard immunochemotherapy regimens that are highly active. Since the mechanism of
action of idelalisib is distinct from rituximab, it is hypothesized that the combination will
be more active than either agent alone. This study will establish initial safety and clinical
activity of idelalisib in combination with rituximab in patients with CLL or SLL. Cohort 2 of
this study will establish safety and clinical activity of idelalisib alone in subjects with
untreated CLL or SLL.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nini Estevez, 6507254041.
Stanford Investigators
View full details
-
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Not Recruiting
More
This randomized phase II trial studies azacitidine with or without entinostat to see how well
they work compared to azacitidine alone in treating patients with myelodysplastic syndromes,
chronic myelomonocytic leukemia, or acute myeloid leukemia. Drugs used in chemotherapy, such
as azacitidine, work in different ways to stop the growth of cancer cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Entinostat may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Giving azacitidine together with entinostat may work better in treating patients with
myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Mai Tran, 6507238594.
Stanford Investigators
View full details
-
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Not Recruiting
More
An open-label, multicenter, phase 1, dose escalation study of MLN4924 in adult patients with
acute myelogenous leukemia (AML), high-grade myelodysplastic syndrome (MDS). The patient
population will consist of adults previously diagnosed with AML including high-grade MDS for
which standard curative, life-prolonging treatment does not exist or is no longer effective.
Stanford is currently not accepting patients for this trial.
For more information, please contact Leonel Gallegos, 6507232781.
Stanford Investigators
View full details
-
A Phase 2 Study With IPI-926 in Patients With Myelofibrosis
Not Recruiting
More
The purpose of this study is to determine the safety and efficacy of IPI-926 in patients with
myelofibrosis (MF) (primary myelofibrosis [PMF], post-polycythemia vera myelofibrosis
[post-PV MF], or post-essential thrombocythemia myelofibrosis [post-ET MF]).
Stanford is currently not accepting patients for this trial.
For more information, please contact Harshdeep Kaur, 6507233589.
Stanford Investigators
View full details
-
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
Not Recruiting
More
The purpose of this study is to determine the dose that can be safely given to see what
effect it may have on your cancer and to determine how the drug is distributed in the body.
Stanford is currently not accepting patients for this trial.
For more information, please contact Michelle Takahashi, 6507364032.
Stanford Investigators
View full details
-
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
Not Recruiting
More
This study will be conducted to assess the maximum tolerated dose (MTD) of panobinostat given
3 times a week (administered on weeks 2 and 3 of a 4 week cycle) in combination with
induction chemotherapy (idarubicin and cytarabine) in newly diagnosed patients with a
cytopathologically confirmed diagnosis of high-risk AML, and to investigate the safety of the
combination in this regimen.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jack Taw, 6507232781.
Stanford Investigators
View full details
-
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study
Not Recruiting
More
This was a randomized, double-blind trial to evaluate deferasirox vs placebo in patients with
myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload .The trial was
conducted in 17 countries, started in 2010 and ended in 2018.
Stanford is currently not accepting patients for this trial.
For more information, please contact Savita Kamble, 6507238594.
Stanford Investigators
View full details
-
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML
Not Recruiting
More
The purpose of this study is to test the safety of vorinostat (Zolinza) and azacitidine
(Vidaza) when combined with gemtuzumab ozogamicin (GO) at different dose levels. These drugs
increase the effect of GO against leukemia cells in the test tube, but we don't know yet
whether they also increase the anti-leukemia effect of GO in people.
Stanford is currently not accepting patients for this trial.
For more information, please contact Leonel Gallegos, 6507232781.
Stanford Investigators
View full details
-
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
Not Recruiting
More
This was a randomized, double-blind study comparing the efficacy and safety of ruxolitinib
(INCB018424) tablets to matching placebo tablets in patients diagnosed with Myelofibrosis
(either Primary Myelofibrosis (PMF) or Post-Polycythemia Vera Myelofibrosis (PPV-MF) or
Post-Essential Thrombocythemia Myelofibrosis (PET-MF).
Stanford is currently not accepting patients for this trial.
For more information, please contact Andrea Linder, 6507254047.
Stanford Investigators
View full details
-
A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia
Not Recruiting
More
The purpose of this study is to evaluate the safety of lenalidomide and to define the maximum
tolerated escalation dose level (MTEDL) when administered by a stepwise dose-escalation
schedule in subjects with relapsed or refractory B-cell CLL.
Stanford is currently not accepting patients for this trial.
For more information, please contact Michelle Takahashi, 6507364032.
Stanford Investigators
View full details
-
Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
Not Recruiting
More
This study seeks to (i) determine a safe and tolerated dose of CYT387 (momelotinib) given to
patients with PMF, post-PV or post-ET and, (ii) assess the effectiveness of
orally-administered CYT387 as a treatment for PMF, post-PV or post-ET.
Stanford is currently not accepting patients for this trial.
For more information, please contact Andrea Linder, 6507254047.
Stanford Investigators
View full details
-
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone
Not Recruiting
More
This randomized phase III trial compares bortezomib, dexamethasone, and lenalidomide with
bortezomib and dexamethasone to see how well they work in treating patients with multiple
myeloma previously treated with dexamethasone. Bortezomib may stop the growth of cancer cells
by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as
dexamethasone, work in different ways to stop the growth of cancer cells, either by killing
the cells or by stopping them from dividing. Lenalidomide may stimulate the immune system in
different ways and stop cancer cells from growing. It is not yet known whether giving
bortezomib and dexamethasone is more effective with or without lenalidomide in treating
multiple myeloma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nancy Mori, 6507240201.
Stanford Investigators
View full details
-
Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
Not Recruiting
More
This extension protocol to the core study CCL09101 allows patients who have tolerated the
drug and derived a clinical benefit, to continue to receive treatment beyond the 9 cycles of
the core protocol. Long term safety and efficacy of CYT387 (momelotinib) will be evaluated.
Stanford is currently not accepting patients for this trial.
For more information, please contact Andrea Linder, 6507254027.
Stanford Investigators
View full details
-
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Not Recruiting
More
This phase II trial is studying the side effects of giving azacitidine together with
gemtuzumab ozogamicin to see how well it works in treating older patients with previously
untreated acute myeloid leukemia. Drugs used in chemotherapy, such as azacitidine, work in
different ways to stop the growth of cancer cells, either by killing the cells or by stopping
them from dividing. Azacitidine may also stop the growth of cancer cells by blocking some of
the enzymes needed for cell growth. Monoclonal antibodies, such as gemtuzumab ozogamicin, can
block cancer growth in different ways. Some block the ability of cancer cells to grow and
spread. Others find cancer cells and help kill them or carry cancer-killing substances to
them. Giving azacitidine together with gemtuzumab ozogamicin may kill more cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Joselene Sipin-Sayno, 6507368113.
Stanford Investigators
View full details
-
Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)
Not Recruiting
More
The purpose of the study is to first determine if temozolomide plus vorinostat in combination
can control relapsed or refractory acute myeloid leukemia (AML) and determine if this
combination can be safely taken. The study will look at the side effects of the Temozolomide
plus Vorinostat in combination and whether the treatment schedule is tolerated.
Stanford is currently not accepting patients for this trial.
For more information, please contact Diana Dobbs, 650-736-6295.
Stanford Investigators
View full details
-
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Not Recruiting
More
The purpose of this study is to determine the safety and effectiveness of different dose
regimens of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia
(CLL).
Stanford is currently not accepting patients for this trial.
For more information, please contact Tessa Hunter, 6507364032.
Stanford Investigators
View full details
-
Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents
Not Recruiting
More
The purpose of this study is to evaluate the effect of Romiplostim (AMG 531) on the incidence
of clinically significant thrombocytopenic events (grade 3 or 4 and/or receipt of platelet
transfusions) in subjects with low or intermediate risk Myelodysplastic Syndrome (MDS)
receiving hypomethylating agents. It is hypothesized that Romiplostim administration, at the
appropriate dose and schedule, will result in reduction in the incidence of clinically
significant thrombocytopenic events in low or intermediate risk MDS subjects receiving
hypomethylating agents.
Stanford is currently not accepting patients for this trial.
For more information, please contact Mai Tran, 6507238594.
Stanford Investigators
View full details
-
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia
Not Recruiting
More
This is a single-center, single arm, open-label study of oral lenalidomide monotherapy
administered to red blood cell (RBC) transfusion dependent adult subjects with
Diamond-Blackfan Anemia (DBA).
Primary Objective: To evaluate the erythroid response rate as measured by rate of red blood
cell transfusion independence [MDS International Working Group (IWG) 2000 Criteria will be
applied].
Secondary Objective: 1)To evaluate the tolerability and safety profile of lenalidomide in
patients with DBA and other inherited marrow failure syndromes 2) To correlate response to
lenalidomide with biologic surrogates of DBA including ribosomal protein mutation status, ex
vivo erythroid colony growth, and microarray gene expression
Stanford is currently not accepting patients for this trial.
For more information, please contact Andrea Linder, 650-725-4047.
Stanford Investigators
View full details
-
Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)
Not Recruiting
More
This is an open label extension study of romiplostim for treatment of thrombocytopenia
(platelet count ≤ 50 x 10^9/L) in MDS subjects. The study is designed to assess the long-term
safety of treatment with romiplostim, as measured by incidence of overall adverse events, the
incidence of bleeding events, the utilization of platelet transfusions, and the duration of
platelet response. The study will further describe the time to disease progression to acute
myeloid leukemia (AML) and survival.
Stanford is currently not accepting patients for this trial.
For more information, please contact Mai Tran, 6507238594.
Stanford Investigators
View full details
-
Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk
Not Recruiting
More
This study will explore the efficacy and safety of a regimen of ON 01910.Na as a 48-hour
continuous intravenous infusion once a week for 3 weeks of a 4-week cycle in MDS patients
with Trisomy 8 or classified as Intermediate-1, -2 or High Risk who are not responding to
current therapeutic options. The rationale for this trial is based upon data from laboratory
studies with ON 01910.Na and upon activity that has been observed in other clinical trials
with ON 01910.Na in patients with MDS.
Stanford is currently not accepting patients for this trial.
For more information, please contact Mai Tran, 6507238594.
Stanford Investigators
View full details
-
Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
Not Recruiting
More
This is a Phase II, open-label, non-randomized study to evaluate the safety, efficacy, and
pharmacokinetics of tamibarotene in adult patients with relapsed or refractory acute
promyelocytic leukemia (APL) following treatment with all-trans-retinoic acid (ATRA) and
arsenic trioxide (ATO). Patients must have received and failed therapy with ATRA and ATO.
Treatment may have been administered either as combination therapy or sequentially as single
agents. Patients who are intolerant to either drug are eligible for this study.
Stanford is currently not accepting patients for this trial.
For more information, please contact Michelle Takahashi, 6507364032.
Stanford Investigators
View full details
-
Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia
Not Recruiting
More
The purpose of this study was to determine the efficacy and safety of twice daily (bid) oral
midostaurin in patients with Aggressive Systemic Mastocytosis (ASM) or Mast Cell Leukemia
(MCL) with or without an Associated Hematological clonal Non-Mast cell lineage Disease
(AHNMD).
Stanford is currently not accepting patients for this trial.
For more information, please contact Andrea Linder, 6507254047.
Stanford Investigators
View full details
-
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Not Recruiting
More
The primary objective of the study is to evaluate the safety of idelalisib in combination
with an anti-CD20 monoclonal antibody (mAb), a chemotherapeutic agent, a mammalian target of
rapamycin (mTOR) inhibitor, a protease inhibitor, an antiangiogenic agent, and/or an
immunomodulatory agent in participants with relapsed or refractory indolent B-cell
non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia
(CLL).
Stanford is currently not accepting patients for this trial.
For more information, please contact Nini Estevez, 650725-4041.
Stanford Investigators
View full details
-
Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
Not Recruiting
More
This study is to evaluate the efficacy and safety of simtuzumab (GS-6624) on bone marrow
fibrosis either alone or in combination with ruxolitinib in participants with primary
myelofibrosis (PMF) and post polycythemia vera or post essential thrombocythemia
myelofibrosis (ET/PV MF).
The study is designed as a two-stage trial. In the stage 1, participants will be randomized
into two cohorts to receive either 200 or 700 mg of study drug. In the stage 2, participants
on ruxolitinib will be randomized to receive either 200 or 700 mg of study drug.
Stanford is currently not accepting patients for this trial.
For more information, please contact Andrea Linder, 6507254047.
Stanford Investigators
View full details
-
An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study
Not Recruiting
More
This is a long-term safety extension study of idelalisib (GS-1101; CAL-101) in patients with
hematologic malignancies who complete other idelalisib studies. It provides the opportunity
for patients to continue treatment as long as the patient is deriving clinical benefit.
Patients will be followed according to the standard of care as appropriate for their type of
cancer. The dose of idelalisib will generally be the same as the dose that was administered
at the end of the prior study, but may be titrated up to improve clinical response or down
for toxicity. Patients will be withdrawn from the study if they develop progressive disease,
unacceptable toxicity related to idelalisib, or if they no longer derive clinical benefit in
the opinion of the investigator.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nini Estevez, 650-725-4041.
Stanford Investigators
View full details
-
Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia
Not Recruiting
More
Open-label, non-randomized, parallel assignment, phase 2 trial assessing the safety and
efficacy of distinct temozolomide treatment regimens for patients with AML and poor prognosis
Stanford is currently not accepting patients for this trial.
For more information, please contact Richa Rajwanshi, 6507364031.
Stanford Investigators
View full details
-
Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm
Not Recruiting
More
This phase II trial is studying how well giving clofarabine and cytarabine together with
filgrastim works in treating patients with newly diagnosed acute myeloid leukemia (AML),
advanced myelodysplastic syndrome (MDS), and/or advanced myeloproliferative neoplasm. Drugs
used in chemotherapy, such as clofarabine and cytarabine, work in different ways to stop the
growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving
the drugs in different doses may kill more cancer cells. Colony stimulating factors, such as
filgrastim, may increase the number of immune cells found in bone marrow or peripheral blood
and may help the immune system recover from the side effects of chemotherapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Leonel Gallegos, 6507232781.
Stanford Investigators
View full details
-
Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
Not Recruiting
More
The primary objective was to compare progression-free survival in adults with relapsed
multiple myeloma who are receiving CRd vs participants receiving Rd in a randomized
multicenter setting.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nini Estevez, 6507254041.
Stanford Investigators
View full details
-
Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia
Not Recruiting
More
We hope to learn more about the clinical efficacy of bortezomib in T-cell prolymphocytic
leukemia. Patients will be selected as a possible participant in this study because they have
a bone marrow disorder known as T-cell prolymphocytic leukemia (T-cell PLL) which does not
tend to respond well to conventional treatment with chemotherapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Richa Rajwanshi, 6507364031.
Lead Sponsor
Stanford Investigators
View full details
-
Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)
Not Recruiting
More
The primary objective of this extension study (GS-US-312-0117) that is a companion study to
Study GS-US-312-0116 (NCT01539512), is to evaluate the effect of idelalisib on the onset,
magnitude, and duration of tumor control. Randomization was done in study GS-US-312-0116, and
carried forward to study GS-US-312-117.
Stanford is currently not accepting patients for this trial.
For more information, please contact Tessa Hunter, 6507364032.
Stanford Investigators
View full details
-
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Not Recruiting
More
The purpose of this study is to compare the effects, good and/or bad, of a standard
chemotherapy regimen for AML that includes the drugs daunorubicin and cytarabine combined
with or without midostaurin (also known as PKC412), to find out which is better. This
research is being done because it is unknown whether the addition of midostaurin to
chemotherapy treatment is better than chemotherapy treatment alone. Midostaurin has been
tested in over 400 patients and is being studied in a number of illnesses, including AML,
colon cancer, and lung cancer. Midostaurin blocks an enzyme, produced by a gene known as
FLT3, that may have a role in the survival and growth of AML cells. Not all leukemia cells
will have the abnormal FLT3 gene. This study will focus only on patients with leukemia cells
with the abnormal FLT3 gene.
Stanford is currently not accepting patients for this trial.
For more information, please contact Leonel Gallegos, 6507232781.
Stanford Investigators
View full details
-
A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis
Not Recruiting
More
The purpose of this study is to evaluate the safety and tolerability of orally administered
TG101348 in patients with myelofibrosis.
Stanford is currently not accepting patients for this trial.
For more information, please contact Andrea Linder, 6507254047.
Stanford Investigators
View full details
-
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
Not Recruiting
More
Primary Objective:
- To evaluate the efficacy of daily oral doses of 400 mg or 500 mg of SAR302503
(Investigational Medicinal Product, IMP) compared to placebo in the reduction of spleen
volume as determined by magnetic resonance imaging (MRI) (or computed tomography scan in
patients with contraindications for MRI).
Secondary Objectives:
- To evaluate the effect on Myelofibrosis (MF)-associated symptoms (key MF symptoms) as
measured by the modified Myelofibrosis Symptom Assessment Form (MFSAF) diary.
- To evaluate the Overall Survival of patients treated with either 400 mg/day or 500
mg/day of IMP as compared to placebo.
- To evaluate the Progression Free Survival of patients treated with either 400 mg/day or
500 mg/day of IMP as compared to placebo.
- To evaluate the durability of splenic response.
- To evaluate the safety of IMP.
Stanford is currently not accepting patients for this trial.
For more information, please contact Harshdeep Kaur, 6507233589.
Stanford Investigators
View full details
-
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients
Not Recruiting
More
The objective is to treat elderly AML and MDS patients with sapacitabine.
Stanford is currently not accepting patients for this trial.
For more information, please contact Michelle Takahashi, 6507364032.
Stanford Investigators
View full details
-
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
Not Recruiting
More
Acute myeloid leukemia (AML) is a cancer of the bone marrow that mostly affects older adults.
Even with the best chemotherapy, two-year disease-free survival is achieved in a minority of
patients. Bone marrow transplantation from a sibling donor may improve cure rates; however,
patients over 50 years of age have a high risk of complications and therefore generally are
excluded from this treatment option. Recently our group developed a transplantation strategy
for older cancer patients that protects against transplant-associated complications, yet does
not interfere with the ability of the transplanted donor cells to destroy cancer cells. With
this new method, we can now safely evaluate transplantation as a curative therapy for AML
patients over the age of 50. We have assembled clinical and scientific researchers throughout
the state of California to study and compare bone marrow transplantation using our new
approach with the best standard of care chemotherapy in AML patients over the age of 50. The
results of this study have the potential to establish a new treatment standard that will
improve survival of older AML patients.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 650-725-1647.
Lead Sponsor
Stanford Investigators
View full details
-
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
Not Recruiting
More
Two-arm, randomized, open-label trial designed to evaluate the efficacy and safety of
bosutinib alone compared to imatinib alone in subjects newly diagnosed with chronic phase
Chronic Myelogenous Leukemia (CML). The primary endpoint is cytogenetic response rate at one
year.
Stanford is currently not accepting patients for this trial.
For more information, please contact Michelle Takahashi, 6507364032.
Stanford Investigators
View full details
-
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia
Not Recruiting
More
Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to
accelerate neutrophil recovery and decrease the risk of febrile neutropenia and infection in
patients receiving chemotherapy for acute lymphoblastic leukemia (ALL), acute myeloid
leukemia (AML), chronic myeloid leukemia (CML), or high-risk myelodysplasia (MDS). In this
study, the safety, tolerability and activity of CLT-008 administered after "standard of care"
cytarabine-based consolidation or induction/re-induction chemotherapy will be determined by
monitoring for adverse reactions, infusion reactions, graft-versus host disease (GVHD),
neutrophil and platelet recovery, hMPC persistence, infections and complications.
Stanford is currently not accepting patients for this trial.
For more information, please contact Andrea Linder, 6507254047.
Stanford Investigators
View full details
-
Investigation of Dysregulated Signaling in MPD Via Multiparameter Phospho-specific Flow Cytometry
Not Recruiting
More
The objective of this study is to better understand the underlying pathogenetic mechanisms of
myeloproliferative disorders (MPDs). We will collect peripheral blood samples from MPD
patients and utilize multiparameter phospho-specific flow cytometry to investigate
dysregulated signaling in blood cells from these patients. This will provide deeper insights
into the pathogenesis of MPDs and may lead to the identification of novel targets for
therapeutic intervention.
Stanford is currently not accepting patients for this trial.
For more information, please contact Stephen Oh, 650-723-7875.
Lead Sponsor
Stanford Investigators
View full details
-
Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Not Recruiting
More
RATIONALE: Vorinostat may stop the growth of cancer cells by interfering with various
proteins needed for cell growth. Monoclonal antibodies, such as gemtuzumab ozogamicin (GO),
can block cancer growth in different ways. GO finds cancer cells and helps kill them by
carrying a cancer-killing substance to them. Giving vorinostat together with gemtuzumab
ozogamicin may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving vorinostat together with gemtuzumab
ozogamicin works in treating older patients with previously untreated acute myeloid leukemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Richa Rajwanshi, 6507364031.
Stanford Investigators
View full details
-
Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease
Not Recruiting
More
RATIONALE: The CAT-8015 immunotoxin can bind tumor cells and kill them without harming normal
cells. This may be an effective treatment for hairy cell leukemia(HCL) that has not responded
to chemotherapy, surgery or radiation therapy.
PURPOSE: Phase I dose escalation study to determine the maximum tolerated dose of CAT-8015
immunotoxin in treating patients who have hairy cell leukemia (HCL) that has not responded to
treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Michelle Takahashi, 6507364032.
Stanford Investigators
View full details
-
Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy
Not Recruiting
More
The primary objective for part 1 of the study is to determine the maximum tolerated dose
(MTD) of CEP-18770 in patients with relapsed and refractory multiple myeloma. The primary
objective for part 2 is to evaluate the antitumor activity of CEP-18770 in patients treated
at the MTD.
Stanford is currently not accepting patients for this trial.
For more information, please contact Leonel Gallegos, 6507232781.
Stanford Investigators
View full details
-
Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM
Not Recruiting
More
The purpose of this trial is to find out the maximum tolerated dose (MTD) of bortezomib
(VELCADE) in combination with pralatrexate in patients with previously treated multiple
myeloma, AL amyloid and Waldenstroem's macroglobulinemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ying Hao, 650-723-0646.
Lead Sponsor
Stanford Investigators
View full details
-
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Giving more than one
drug (combination chemotherapy) may kill more cancer cells.
PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating
young patients with newly diagnosed acute lymphoblastic leukemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Joselene Sipin-Sayno, 6507368113.
Stanford Investigators
View full details
-
Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)
Not Recruiting
More
This study has a phase 1 and a phase 2 component.
In phase 1, the objective is to determine the maximum tolerated dose (MTD) of lenalidomide
when after azacitidine.
In phase 2, the objective is to determine the efficacy of the combination treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Leonel Gallegos, 6507232781.
Lead Sponsor
Stanford Investigators
View full details
-
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
Not Recruiting
More
The purpose of this study is to evaluate the long-term effects of orally administered
SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001
study.
Stanford is currently not accepting patients for this trial.
For more information, please contact Andrea Linder, 6507254047.
Stanford Investigators
View full details
-
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
Not Recruiting
More
The purpose of this study is to compare the safety and efficacy of Lenalidomide plus low dose
dexamethasone to that of the combination of melphalan, prednisone and thalidomide.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nini Estevez, 6507254041.
Stanford Investigators
View full details
-
S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Not Recruiting
More
RATIONALE: Monoclonal antibodies, such as epratuzumab, can block cancer growth in different
ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such
as cytarabine and clofarabine, work in different ways to stop the growth of cancer cells,
either by killing the cells or by stopping them from dividing. Giving epratuzumab together
with cytarabine and clofarabine may kill more cancer cells.
PURPOSE: This phase II trial is studying the side effects and how well giving epratuzumab
together with cytarabine and clofarabine works in treating patients with relapsed or
refractory acute lymphoblastic leukemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nini Estevez, 6507254041.
Stanford Investigators
View full details
